ANDA 207465, held by Cipla. Metoprolol Succinate.
As of Nov 16, 2026, ANDA 207465 (Metoprolol Succinate), held by Cipla, was first approved by FDA on Oct 26, 2018, with 2 approved supplements and 0 published complete response letters.
Metoprolol succinate extended-release tablets are beta-adrenergic blocker indicated for the treatment of:: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. Angina Pectoris. Heart Failure -, to reduce the risk of cardiovascular mortality and heart failure hospitalization ins patients with heart failure 1.1 Hypertension Metoprolol succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 26, 2018 | Original application | Approved | None posted |
| Metoprolol SuccinateEQ 50MG TARTRATE · tablet, extended release;oral | Metoprolol Succinate | Rx |
| Metoprolol SuccinateEQ 100MG TARTRATE · tablet, extended release;oral | Metoprolol Succinate | Rx |
| Metoprolol SuccinateEQ 200MG TARTRATE · tablet, extended release;oral | Metoprolol Succinate | Rx |
| Jul 22, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jul 22, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| Oct 26, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters